THERMO FISHER SCIENTIFIC INC. (NYSE:TMO) Files An 8-K Regulation FD Disclosure

Effective January 1, 2017, to further align our products and commercial teams to better serve our customers, Thermo Fisher Scientific Inc. (the company) transferred its plastics for cell culture and vaccines/biologics; sample preparation and analysis; and production chemicals product lines to the Life Sciences Solutions segment from the Laboratory Products and Services segment and transferred its biochemical product line from the Life Sciences Solutions segment to the Laboratory Products and Services segment. These moves are consistent with the company’s historical practice of moving a product line between segments when a shift in strategic focus of either the product line or a segment more closely aligns the product line with a segment different than that in which it had previously been reported.

Also effective January 1, 2017, the company adopted Accounting Standards Update (ASU) 2016-09>“Improvements to Employee Share-based Payment Accounting.” The company has retrospectively applied the amendments relating to the statement of cash flows presentation of excess tax benefits and employee taxes paid when the company withholds shares to meet the withholding requirement. As a result, cash flows from operating activities and from financing activities have changed from those presented in prior periods. The amendment requiring recognition of excess tax benefits in the income statement has been applied prospectively as required by the ASU and, accordingly, only the net income of future periods will be affected by this part of the rule changes.

The company’s first-quarter 2017 financial report will be the first to reflect the new segment structure and revised statement of cash flows. On April 17, 2017, the company made available on its corporate website unaudited historical financial data that has been recast to reflect its new segment reporting structure and revised operating cash flow data. The recast financial data is available at www.thermofisher.com under the headings “Investors” and “GAAP/Non-GAAP Reconciliation & Financial Package.”

About THERMO FISHER SCIENTIFIC INC. (NYSE:TMO)
Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Through the Life Sciences Solutions segment, it provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of disease. Through the Analytical Instruments segment, it provides instruments, consumables, software and services. The Specialty Diagnostics segment offers diagnostic test kits, reagents, culture media, instruments and associated products. The Laboratory Products and Services segment offers self-manufactured and sourced products for the laboratory. THERMO FISHER SCIENTIFIC INC. (NYSE:TMO) Recent Trading Information
THERMO FISHER SCIENTIFIC INC. (NYSE:TMO) closed its last trading session down -0.26 at 152.18 with 934,603 shares trading hands.